CN113834936A - Application of growth differentiation factor 9 in predicting embryonic development potential - Google Patents

Application of growth differentiation factor 9 in predicting embryonic development potential Download PDF

Info

Publication number
CN113834936A
CN113834936A CN202110959640.5A CN202110959640A CN113834936A CN 113834936 A CN113834936 A CN 113834936A CN 202110959640 A CN202110959640 A CN 202110959640A CN 113834936 A CN113834936 A CN 113834936A
Authority
CN
China
Prior art keywords
embryo
culture solution
gdf9
predicting
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110959640.5A
Other languages
Chinese (zh)
Inventor
李竞宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202110959640.5A priority Critical patent/CN113834936A/en
Publication of CN113834936A publication Critical patent/CN113834936A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0604Whole embryos; Culture medium therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998Proteins not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/495Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides an application of a growth differentiation factor 9 in predicting embryonic development potential. Belongs to the technical field of assisted reproduction. To provide a safe and non-invasive indication of the potential for embryonic development. The method comprises the steps of obtaining an embryo culture solution, determining the absorbance of the embryo-free culture solution, determining the absorbance of a GDF9 standard solution and the concentration of a GDF9 standard solution as standard curves; and comparing the absorbance of the embryo culture solution with the standard curve to obtain the concentration of the GDF9 in the embryo culture solution, evaluating the development potential of the embryo by using the concentration of the GDF9, and not needing to carry out biopsy on the embryo, so that the method has the advantages of no wound, and can improve the survival rate of a single assisted reproductive treatment cycle, and has higher clinical significance.

Description

Application of growth differentiation factor 9 in predicting embryonic development potential
Technical Field
The invention belongs to the technical field of assisted reproduction, and particularly relates to application of a growth differentiation factor 9 in predicting embryonic development potential.
Background
With the progress of bioscience, Assisted Reproductive Technologies (ART) have been greatly developed in recent years, especially in the field of IVF laboratory technologies, but clinical outcomes still exist in unsatisfactory places. The us CDC publishes the latest 2017 full american ART data showing: for patients with the age of less than 35 years, the implantation rate of the transplanted embryo is only 37.1 percent; with the age increasing, the embryo implantation rate is also reduced, which is respectively: 27.5% (35-37 years old), 18.3% (38-40 years old), 9.7% (41-42), 4.1% (43-44), in the assisted pregnancy patients above 45 years old, the embryo is freshly implanted by 2.2%.
The current research shows that embryo selection is an important factor influencing embryo implantation, and the embryo implantation rate can be improved only by selecting the embryo with the most planting potential. How to screen out embryos with implantation potential for transplantation is the key for improving the success rate of ART and is a hotspot and difficulty in the reproductive field. The existing commonly used embryo selection technology is embryo morphology scoring, the quality of the embryo is mainly judged by evaluating the development speed, the size of blastomeres, fragments, vacuoles and the like of the embryo, and the method has the defects that the subjective factors of evaluation are large, the difference between different technicians and different laboratories is large, and the quality of the embryo cannot be quantified. In addition, the morphology of the embryo sometimes does not completely reflect the embryo's planting potential. Therefore, it is important to find a safe and non-invasive indication of embryo quality before early embryo transfer.
Disclosure of Invention
The invention aims to provide a safe and noninvasive marker of embryo development potential.
The invention provides an application of a growth differentiation factor 9 in prediction or auxiliary prediction of embryonic development potential.
The invention provides an application of a growth differentiation factor 9 in prediction or auxiliary prediction of embryo quality.
Further defined, the embryo is selected at the stage of the third day after fertilization.
Further defined, the detection method of the growth differentiation factor 9 is to detect by using a microplate reader.
Further defined, the method of culturing embryos is as follows: the fertilized embryos are placed into pre-balanced embryo culture drops in the cleavage stage for culture, the culture environment is 37 ℃, and the volume fraction of the culture environment is 5 percent of oxygen and the volume fraction of the culture environment is 6 percent of carbon dioxide.
Further defined, the pre-balanced cleavage stage embryo culture drop is formulated as an embryo culture solution G1-plus containing 5% HSA by mass volume fraction.
The invention provides a kit for predicting or assisting in predicting embryonic development potential, which comprises: a sample to be detected, a standard substance, a quality control substance and biotin.
Has the advantages that: the invention particularly relates to a method for predicting embryo development potential by detecting GDF9 level in human embryo in-vitro culture solution, wherein the GDF9 content in the embryo culture solution of the third day is obviously related to the embryo development potential. Where developmental potential refers to the likelihood of an embryo being implanted or developing into a fetus. The method does not need to carry out biopsy on the embryo, has the advantage of non-invasiveness, can improve the survival rate of a single assisted reproductive treatment cycle, shortens the treatment cycle of an infertility patient, and has higher clinical significance.
Drawings
FIG. 1 is a graph showing the relationship between embryo quality and GDF9 content in embryo culture fluid; A. GDF9 content in transplantable and non-transplantable embryo culture solutions; B. GDF9 content in high quality (good) embryo culture solution, medium quality (fair) embryo culture solution, and low quality (poor) embryo culture solution; the ordinate is the content of GDF9 and the abscissa is the group.
FIG. 2 shows GDF9 content in culture media corresponding to implanted and non-implanted embryos; the ordinate is the content of GDF9 and the abscissa is the group.
FIG. 3 shows GDF9 content in culture solution corresponding to live embryos and embryos not obtained; the ordinate is the content of GDF9 and the abscissa is the group.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
A commercial embryo culture solution G1-plus (Vitroffe, Sweden).
Sources of embryo culture solution: ovum is taken out after controlled superovulation, fertilization situation is observed 17-20 hours after insemination, 2PN embryo is selected to be transferred into a single liquid drop (G1+ 5% HSA) of embryo culture solution in a cleavage period balanced overnight to be continuously cultured for the third day, and residual culture solution after embryo transplantation is collected according to the standard of 10 mu L/drop.
Live embryo culture solution: after controlled hyperstimulation, ova are taken out, fertilization conditions are observed 17-20 hours after insemination, 2PN embryos are selected to be transferred into overnight balanced embryo culture solution in the cleavage stage (G1+ 5% HSA, 30 mu L/drop) and are continuously cultured for the third day, the rest culture solution after embryo transplantation is collected according to the standard of 10 mu L/drop, and only in the later stage identification, the embryos are embryos which can successfully produce live fetuses after embryo transplantation.
Implanted embryo culture solution: taking out ovum after controlled superovulation, observing fertilization situation 17-20 hours after insemination, selecting single liquid drop of 2PN embryo transferred into overnight balanced embryo culture solution in cleavage stage (G1+ 5% HSA) to continue culturing to the third day, and collecting the residual culture solution after embryo transplantation according to the standard of 10 mul/drop, wherein the embryo is the embryo which can successfully produce live fetus after embryo transplantation in later stage identification.
Example 1.
1. Obtaining a culture solution of embryos: the fertilized embryos are put into pre-balanced embryo culture drops (G1+ 5% HSA recombinant human serum albumin) in the cleavage stage for continuous culture under the culture environment of 37 ℃, 5% of oxygen and 6% of carbon dioxide, the embryo evaluation is carried out according to the traditional morphology scores including cleavage speed, fragmentation degree, blastomere uniformity, the presence of single or multiple blastomeres and the like, the third day of transplantable embryos are defined as embryos with the number of blastomeres not less than 6, fragments less than 30% and no obvious morphological abnormality, and good-quality embryo culture solution and poor-quality embryo culture solution are obtained.
2. Detecting the content of GDF9 (growth factor 9) in the embryo culture solution with good quality and the embryo culture solution with poor quality: determining the absorbance of the embryo culture solution with good quality and the embryo culture solution with poor quality; determining the absorbance of the culture solution without the embryo, the absorbance of the GDF9 standard solution and the concentration of the GDF9 standard solution as standard curves; comparing the embryo culture solution absorbance with the standard curve to obtain the concentration of GDF9 in the embryo culture solution, and using the concentration of GDF9 to evaluate the embryo development potential.
3. The results are shown in fig. 1, the content of GDF9 in the culture solution of the third day is significantly related to the quality of the embryo, wherein the content of GDF9 in the culture solution corresponding to the embryo with better embryo quality is significantly lower.
3. Detecting the content of GDF9 in the implanted embryo culture solution and the non-implanted embryo culture solution: determining the absorbance of the embryo culture solution with good quality and the embryo culture solution with poor quality; determining the absorbance of the culture solution without the embryo, the absorbance of the GDF9 standard solution and the concentration of the GDF9 standard solution as standard curves; comparing the embryo culture solution absorbance with the standard curve to obtain the concentration of GDF9 in the embryo culture solution, and using the concentration of GDF9 to evaluate the embryo development potential.
The results are shown in fig. 2, the GDF9 content in the culture solution of the third day is significantly related to the implantation rate, wherein the culture solution corresponding to the implanted embryo has significantly lower GDF9 content.
4. Detecting the GDF9 content in the live embryo culture solution and the embryo culture solution without live birth: determining the absorbance of the embryo culture solution with good quality and the embryo culture solution with poor quality; determining the absorbance of the culture solution without the embryo, the absorbance of the GDF9 standard solution and the concentration of the GDF9 standard solution as standard curves; comparing the embryo culture solution absorbance with the standard curve to obtain the concentration of GDF9 in the embryo culture solution, and using the concentration of GDF9 to evaluate the embryo development potential.
The results are shown in fig. 3, the GDF9 content in the culture fluid of the third day is significantly correlated with live birth, wherein the culture fluid corresponding to embryos obtained from live birth has significantly lower GDF9 content.
5. GDF9 in the culture fluid of the third day can be used as a marker for non-invasive assessment of the potential for embryo development. During embryo screening, GDF9 content in an embryo culture solution can be sequenced to serve as an auxiliary noninvasive evaluation method.
Example 2A kit for predicting or aiding in the prediction of the potential of embryonic development
Firstly, the components of the kit: detection samples, standard substances, quality control substances and biotin, concentrated washing solution A, GDF-9 experiment buffer solution, biotin conjugate and TMB substrate solution.
II, GDF9 detection method:
1. equilibrating all reagents and samples to room temperature;
2. dissolving standard products B-F (respectively containing 48pg, 222pg, 775pg, 2550pg and 5800pg of recombinant human GDF9 protein) and a quality control product I, II (respectively containing 400pg of recombinant human GDF9 protein 240-containing and 4302pg of recombinant human GDF 9-containing protein 2868-containing) by 1mL of deionized water respectively, dissolving, whirling and uniformly mixing;
3. diluting the concentrated washing solution A (phosphate buffer solution containing nonionic detergent) with deionized water by 25 times;
4. diluting the sample to a proper multiple with a fresh blank culture solution (embryo culture solution in the cleavage stage);
5. marking the microporous strip;
6. respectively adding 50 mu L of calibrator, quality control material and sample into corresponding micropores;
7. add 50. mu.L of GDF-9 assay buffer (phosphate buffer with bovine serum albumin) to each well;
8. incubating for 3 hours at room temperature with shaking on a microplate orbital shaker (600-;
9. the biotin conjugate (protein-based buffer containing the detection antibody biotin complex) was diluted 50-fold 20-30 minutes before the incubation was completed. Accurately sucking 220 mu L of concentrated solution into 11mL of diluted solution by the whole plate operation;
10. washing the plate for 5 times;
11. add 100. mu.L of diluted biotin conjugate per well;
12. incubating with shaking on a microplate orbital shaker (600-;
13. washing the plate for 5 times;
14. add 100. mu.L of streptavidin conjugate per well (ready-to-use);
15. incubation with shaking on a microplate orbital shaker (600-;
16. washing the plate for 5 times;
17. 100 μ L of TMB substrate was added to each well. Attention is paid to avoiding direct sunlight;
18. incubation with shaking on a microplate orbital shaker (600-;
19. add 100. mu.L of stop buffer to each well. Reading with microplate reader at 450nm wavelength within 20 min.
Example 3A method for predicting embryonic development potential for non-therapeutic and diagnostic purposes
1. Selecting a plurality of embryo culture solutions to be implanted into the same person, wherein the source and the period of the embryo culture solutions are the same as those in the embodiment 1;
2. the kit of example 2 is used to detect the content of the growth factor 9 in the embryo culture solution in step 1, and the embryo with the lowest content of the growth factor-9 is selected as the embryo with the highest development potential.

Claims (7)

1. The application of the growth differentiation factor 9 in predicting or assisting in predicting the development potential of embryos.
2. The application of the growth differentiation factor 9 in predicting or assisting in predicting the quality of the embryo.
3. Use according to claim 1 or 2, wherein the embryo is selected at a time period of three days after fertilization.
4. The use according to claim 1 or 2, wherein the growth differentiation factor 9 is detected by a microplate reader.
5. Use according to claim 1 or 2, wherein the method of culturing embryos is as follows: the fertilized embryos are placed into pre-balanced embryo culture drops in the cleavage stage for culture, the culture environment is 37 ℃, and the volume fraction of the culture environment is 5 percent of oxygen and the volume fraction of the culture environment is 6 percent of carbon dioxide.
6. The use of claim 5, wherein the pre-equilibrated embryo culture drop at the cleavage stage is formulated as embryo culture broth G1-plus containing 5% by volume of HSA.
7. A kit for predicting or aiding in the prediction of embryonic development potential, the kit comprising: a sample to be detected, a standard substance, a quality control substance and biotin.
CN202110959640.5A 2021-08-20 2021-08-20 Application of growth differentiation factor 9 in predicting embryonic development potential Pending CN113834936A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110959640.5A CN113834936A (en) 2021-08-20 2021-08-20 Application of growth differentiation factor 9 in predicting embryonic development potential

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110959640.5A CN113834936A (en) 2021-08-20 2021-08-20 Application of growth differentiation factor 9 in predicting embryonic development potential

Publications (1)

Publication Number Publication Date
CN113834936A true CN113834936A (en) 2021-12-24

Family

ID=78960994

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110959640.5A Pending CN113834936A (en) 2021-08-20 2021-08-20 Application of growth differentiation factor 9 in predicting embryonic development potential

Country Status (1)

Country Link
CN (1) CN113834936A (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050672A1 (en) * 1998-04-01 1999-10-07 Baylor College Of Medicine Assay for growth differentiation factor 9
CN102576027A (en) * 2009-08-22 2012-07-11 里兰斯坦福初级大学理事会 Imaging and evaluating embryos, oocytes, and stem cells
WO2014018404A1 (en) * 2012-07-21 2014-01-30 Baylor College Of Medicine Gdf9:bmp15 heterodimers for enhancing fertility
CA3058678A1 (en) * 2017-02-01 2018-08-09 Newsouth Innovations Pty Limited Gamete-secreted growth factors
CN111073848A (en) * 2020-01-02 2020-04-28 广州裕康生物科技有限公司 Cleavage stage embryo culture composition and cleavage stage embryo culture solution
CN112725263A (en) * 2021-01-26 2021-04-30 东北农业大学 Porcine oocyte in-vitro maturation culture solution with polyspermy inhibition effect and preparation method and application thereof

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050672A1 (en) * 1998-04-01 1999-10-07 Baylor College Of Medicine Assay for growth differentiation factor 9
CN102576027A (en) * 2009-08-22 2012-07-11 里兰斯坦福初级大学理事会 Imaging and evaluating embryos, oocytes, and stem cells
WO2014018404A1 (en) * 2012-07-21 2014-01-30 Baylor College Of Medicine Gdf9:bmp15 heterodimers for enhancing fertility
CA3058678A1 (en) * 2017-02-01 2018-08-09 Newsouth Innovations Pty Limited Gamete-secreted growth factors
WO2018141015A1 (en) * 2017-02-01 2018-08-09 Newsouth Innovations Pty Limited Gamete-secreted growth factors
AU2018214444A1 (en) * 2017-02-01 2019-09-19 Anlagen Pty Ltd Gamete-secreted growth factors
KR20190121781A (en) * 2017-02-01 2019-10-28 뉴사우스 이노베이션즈 피티와이 리미티드 Germ cell-secreted growth factors
EP3577457A1 (en) * 2017-02-01 2019-12-11 Newsouth Innovations Pty Limited Gamete-secreted growth factors
US20200041523A1 (en) * 2017-02-01 2020-02-06 Newsouth Innovations Pty Limited Gamete-secreted growth factors
CN110914686A (en) * 2017-02-01 2020-03-24 新南创新私人有限公司 Gamete secreted growth factor
CN111073848A (en) * 2020-01-02 2020-04-28 广州裕康生物科技有限公司 Cleavage stage embryo culture composition and cleavage stage embryo culture solution
CN112725263A (en) * 2021-01-26 2021-04-30 东北农业大学 Porcine oocyte in-vitro maturation culture solution with polyspermy inhibition effect and preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
徐清华等: "单卵母细胞对应的卵丘颗粒细胞中生长分化因子-9和骨形成蛋白-15的表达水平与胚胎发育潜能的研究", 中国优生与遗传杂志, no. 09, pages 120 - 127 *

Similar Documents

Publication Publication Date Title
KR101747983B1 (en) Imaging and evaluating embryos, oocytes, and stem cells
Montag et al. New approaches to embryo selection
CN103074410B (en) Embryo quality assessment based on blastomere division and motion
ES2657927T3 (en) Aneuploidy detection methods in human embryos
Ivec et al. Prediction of human blastocyst development from morulas with delayed and/or incomplete compaction
CN1798853A (en) Non-invasive prenatal genetic diagnosis using transcervical cells
US9404908B2 (en) Non-invasive imaging to the blastocyst stage for the detection of human embryonic aneuploidy
CN102459635A (en) Methods for selecting oocytes and competent embryos with high potential for pregnancy outcome
Zhou et al. Relationship of polar bodies morphology to embryo quality and pregnancy outcome
US6879713B1 (en) Meiotic spindle imaging in oocytes and uses therefor in in vitro fertilization
Gu et al. The correlation analysis of human embryonic MMP-9 secretion and embryo quality.
CN113834936A (en) Application of growth differentiation factor 9 in predicting embryonic development potential
Tabibnejad et al. Assessing ICSI outcome by combining non‐invasive indicators: early time‐lapse morphokinetics and apoptosis in associated cumulus cells among women with the polycystic ovarian syndrome
CN114875108A (en) In vitro embryo development potential prediction and evaluation technology based on glucose and glutamine level test
WO2016036697A1 (en) Methods of detecting embryo mosaicism
CN103713120A (en) Method for judging cell state in body liquid environment based on liquid-phase chip technology
RU2593740C1 (en) Method of controlling degree of zygosity of pregnancy in extracorporeal fertilisation and embryo transfer programs
Flynn CD95 and the MRL-lpr Mouse Model
CN110361534A (en) It assesses embryo and predicts chemical markers and its application of success rate in vitro fertilization
Aghajani et al. The impact of maternal age on chromosomal aneuploidy, blastocyst quality, and pregnancy outcomes during intracytoplasmic sperm injection cycles
CN108982867B (en) A method of quality of blastocysts is judged using protein chip
WO2015001458A1 (en) Embryo assessment method
Gao et al. A COMPARISON OF IVF EMBRYOLOGY OUTCOMES IN LUTEAL PHASE VERSUS FOLLICULAR PHASE CONTROLLED OVARIAN HYPERSTIMULATION CYCLES
Hannah Time-lapse technology in the IVF laboratory. Assessing safety and human embryo development
Guidobono et al. P-147 Number of autologous mature oocytes as a predictor of live birth rate in women aged over 40 who do not accept egg donation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20211224